Precision Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others), By Product & Services (Consumables (Kits & Reagents), Equipment, Services), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others), By End-Use (Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 15.78 Billion
CAGR (2026-2031)	5.83%
Fastest Growing Segment	Oncology
Largest Market	North America
Market Size (2031)	USD 22.17 Billion

Market Overview

The Global Precision Genomic Testing Market will grow from USD 15.78 Billion in 2025 to USD 22.17 Billion by 2031 at a 5.83% CAGR. Precision genomic testing constitutes the analysis of biological samples to identify specific genetic alterations that influence disease susceptibility and treatment response. The market expansion is primarily propelled by the increasing prevalence of chronic diseases and the declining costs associated with advanced sequencing technologies which necessitate accurate molecular diagnostics for targeted therapeutic interventions. According to the World Health Organization, in 2024, global cancer cases were predicted to rise by more than 75% by 2050, highlighting the critical demand for scalable diagnostic modalities to manage this rising burden.

Despite the market growth, the sector faces substantial challenges related to the complex regulatory landscape and reimbursement limitations. Inconsistent insurance coverage for comprehensive genomic profiling often restricts patient access and creates financial barriers for healthcare providers. Consequently, the high capital expenditure required for establishing testing infrastructure combined with uncertain reimbursement policies serves as a major restraint that could hinder the broader adoption of these diagnostic solutions globally.

Key Market Drivers

The adoption of liquid biopsy for early cancer detection represents a primary catalyst for market expansion, fundamentally shifting oncology from reactive tissue sampling to proactive, non-invasive blood-based monitoring. This technology enables clinicians to identify circulating tumor DNA with high sensitivity, facilitating the detection of minimal residual disease and the tailoring of personalized therapies without the risks associated with surgical procedures. The urgency for such scalable diagnostics is highlighted by the growing burden of disease; according to the American Cancer Society, in 2025, it was projected that over 2,041,000 new cancer cases would be diagnosed in the United States alone. Consequently, leading diagnostic providers are witnessing substantial uptake of these solutions. According to Natera, Inc., February 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported a 56.7% year-over-year increase in total annual revenues, primarily driven by the rapid volume growth of its liquid biopsy and genetic testing portfolio.

Concurrently, increasing government funding for population genomics is establishing the infrastructure necessary for broad-based precision medicine. National initiatives are investing heavily to sequence vast cohorts, creating diverse genomic biobanks that accelerate drug discovery and clarify the genetic underpinnings of complex diseases across underrepresented populations. This state-sponsored push is dramatically expanding the volume of clinical-grade data available for research, thereby fueling demand for high-throughput sequencing technologies. For instance, according to the National Institutes of Health, February 2025, in the 'All of Us Research Program Data Expansion' announcement, the initiative released whole genome sequences from more than 414,000 participants, marking a nearly 70% increase in the genomic dataset accessible to researchers. This influx of public capital and data serves as a critical engine for the wider adoption of genomic testing technologies globally.

Download Free Sample Report

Key Market Challenges

Reimbursement Limitations and Inconsistent Insurance Coverage

The Global Precision Genomic Testing Market is significantly hampered by reimbursement limitations and inconsistent insurance coverage, which act as primary barriers to the widespread adoption of comprehensive genomic profiling. While sequencing costs have declined, the lack of standardized reimbursement policies among private and public payers creates a financially precarious environment for clinical laboratories and healthcare providers. Insurers often classify advanced genomic tests as experimental or investigational, leading to frequent claim denials or requirements for extensive prior authorization. This uncertainty discourages physicians from ordering these essential diagnostics, as they fear leaving patients with substantial out-of-pocket expenses or absorbing the costs themselves.

Furthermore, these administrative hurdles disrupt the workflow of medical practices, forcing them to allocate significant resources to navigate complex approval processes rather than patient care. The unpredictability of payment models stifles market growth by limiting the capital available for laboratories to invest in testing infrastructure. According to the American Medical Association, in 2024, 94% of physicians reported that prior authorization protocols—often utilized by insurers to manage coverage for advanced medical services—resulted in delays in patient care. This statistic underscores the operational severity of reimbursement barriers, which directly restrict patient access to precision medicine and curtail the market's expansion potential.

Key Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) is reshaping the market by automating complex variant interpretation and enabling the analysis of vast multi-modal datasets. As genomic sequencing generates massive data volumes, traditional bioinformatics pipelines face bottlenecks that AI algorithms resolve by identifying pathogenic variants with improved speed and accuracy. This technological shift is driving significant commercial growth for entities that successfully deploy AI-driven clinical data platforms to support precision medicine. According to Tempus AI, February 2025, in the 'Tempus Reports Fourth Quarter and Full Year 2024 Results', the company's Data and Services segment generated $241.6 million in annual revenue, representing a 43.2% year-over-year increase, highlighting the expanding value of AI-enabled genomic insights.

The proliferation of companion diagnostic (CDx) collaborations is intensifying as pharmaceutical developers increasingly rely on precision testing to guide the administration of targeted therapies. This trend involves diagnostic providers partnering with biopharmaceutical firms during early-stage clinical trials to validate comprehensive genomic profiling assays alongside novel drugs, rather than retrospectively. These partnerships are substantially increasing test volumes related to drug development and clinical trial enrollment, creating a reliable revenue stream for testing providers. According to Guardant Health, January 2025, in the 'Preliminary Fourth Quarter and Full Year 2024 Results', the company reported a 35% year-over-year increase in biopharma test volumes, totaling approximately 40,500 tests, driven by demand from partners for its precision oncology solutions.

Segmental Insights

The oncology segment currently registers the most rapid expansion within the global precision genomic testing market. This growth is primarily driven by the increasing global prevalence of cancer and a significant shift toward personalized medicine, which necessitates precise genetic profiling for effective treatment planning. Furthermore, the rising approval of companion diagnostic tests by regulatory authorities such as the U.S. FDA supports this trend, as these assays are essential for identifying patients eligible for specific targeted therapies. Consequently, substantial investments in cancer research and genomic profiling continue to accelerate demand within this sector.

Regional Insights

North America maintains a dominant position in the precision genomic testing market due to high healthcare expenditure and the presence of major biotechnology corporations. The growth is further sustained by robust government support for precision medicine research, particularly through programs funded by the National Institutes of Health. Additionally, the U.S. Food and Drug Administration provides a structured regulatory framework that facilitates the commercialization of new diagnostic assays. These factors, combined with established reimbursement models, ensure widespread adoption of genomic testing services throughout the region.

Recent Developments

• In January 2025, Illumina announced a strategic collaboration with a global leader in AI computing to advance the analysis and interpretation of multiomic data. This partnership aimed to integrate artificial intelligence with genomic sequencing data to accelerate drug discovery and clinical research. By enabling genomic algorithms on accelerated computing platforms, the companies sought to expand the accessibility of multiomics analysis and democratize genomics for identifying new drug targets. The initiative focused on delivering powerful AI-driven insights to pharmaceutical companies and researchers to streamline genomic data generation and interpretation for precision health applications.
• In October 2024, Exact Sciences received approval from the U.S. Food and Drug Administration for its next-generation multi-target stool DNA test, Cologuard Plus. The test was designed to screen for colorectal cancer in average-risk adults aged 45 and older. This new version featured novel biomarkers and improved laboratory processes, which demonstrated increased specificity and sensitivity compared to the previous generation. The approval marked a significant advancement in non-invasive screening options, aiming to reduce false positives and minimize unnecessary follow-up colonoscopies, thereby improving the efficiency of colorectal cancer screening programs.
• In August 2024, Qiagen announced the expansion of its master collaboration agreement with AstraZeneca to develop and commercialize companion diagnostics for chronic diseases. The expanded partnership focused on leveraging Qiagen’s syndromic testing platform to develop genotyping assays for disease areas beyond oncology, such as chronic liver disease. This collaboration aimed to enable specialty care providers to perform rapid genomic profiling during routine clinical examinations, facilitating faster decision-making for patient eligibility for genomically targeted medicines. The initiative underscored the growing application of precision medicine technologies in managing complex chronic conditions.
• In July 2024, Guardant Health obtained approval from the U.S. Food and Drug Administration for its Shield blood test for colorectal cancer screening. This approval established the test as a primary screening option for average-risk adults aged 45 and older, making it the first blood test to meet the performance requirements for Medicare coverage in this indication. The test utilized a blood draw to detect colorectal cancer signals, offering a convenient alternative to invasive procedures like colonoscopies. The company highlighted that this development would help improve screening adherence rates by providing a more accessible and less invasive testing method for patients.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

By Technology	By Product & Services	By Application	By End-Use	By Region
Next-Generation Sequencing Polymerase Chain Reaction Microarray Technology Sanger Sequencing CRISPR/Cas Systems Others	Consumables (Kits & Reagents) Equipment Services	Oncology Cardiovascular Diseases Neurological Disorders Reproductive Health Rare Diseases Others	Hospitals and Clinics Diagnostic Laboratories Research & Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Precision Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Precision Genomic Testing Market, By Technology:

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

• Precision Genomic Testing Market, By Product & Services:

• Consumables (Kits & Reagents)
• Equipment
• Services

• Precision Genomic Testing Market, By Application:

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

• Precision Genomic Testing Market, By End-Use:

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others

• Precision Genomic Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE